[Endolymphatic polychemotherapy in comprehensive treatment of pulmonary cancer after a radical surgery].
Introduction of chemopreparations in lymphatic vessels are easily tolerated by patients, permitting to enhance in 1.5-2 times their dosage and to reduce the introduction duration. Application of adjuvant endolymphatical polychemotherapy for a nonsmall cell pulmonary cancer in cases of tumor size more than 5 cm and (or) presence of metastases in regional lymphatic nodes in comparison with generally accepted polychemotherapy promotes the index of a one-year survival increase from 72 to 81.8%, three-year one-from 38 to 52.3% and five-year-from 28 to 38.6%.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000601:surgery*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D006801:Humans; D007272:Injections, Intralymphatic; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D008207:Lymphatic Metastasis; D012189:Retrospective Studies; D016896:Treatment Outcome